Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT PROPOSED REORGANISATION AT CONTROLLING SHAREHOLDER LEVEL

This announcement is made by Sisram Medical Ltd (the "**Company**") on a voluntary basis.

On 8 April 2026, the board of directors of the Company (the "**Board**") was notified by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("**Fosun Pharma**"), a controlling shareholder of the Company, that in order to optimize the internal reorganisation, two of its indirect wholly-owned subsidiaries, Ample Up Limited ("**Ample Up**") and Chindex Medical Limited ("**Chindex**"), had entered into share transfer agreements (the "**Agreements**") on the same day, respectively, with Fosun Pharma Industrial Pte. Ltd. ("**FPI**"), another indirect wholly-owned subsidiary of Fosun Pharma.

Pursuant to the Agreements, Ample Up agreed to transfer its entire holding of 207,186,160 shares of the Company (representing approximately 44.24% of the total issued shares of the Company as at the date of this announcement) and Chindex agreed to transfer its entire holding of 127,318,640 shares of the Company (representing approximately 27.18% of the total issued shares of the Company as at the date of this announcement) to FPI (the "**Proposed Reorganisation**"). Completion of the Proposed Reorganisation is subject to the satisfaction of certain conditions.

The Proposed Reorganisation would result in FPI acquiring 71.42% of the voting rights of the Company, which would trigger the mandatory general offer obligation under The Codes on Takeovers and Mergers and Share Buy-backs upon completion. Accordingly, Fosun Pharma has applied for, and the Securities and Futures Commission granted, a waiver from the obligation to make a general offer for the shares in the Company as a result of the Proposed Reorganisation.

As at the date of this announcement, Fosun Pharma, through its indirect wholly-owned subsidiaries Ample Up and Chindex, holds 334,504,800 shares of the Company, representing approximately 71.42% of the total issued shares. Immediately following the completion of the Proposed Reorganisation, Fosun Pharma, through its indirect wholly-owned subsidiary FPI, will hold the same 334,504,800 shares. And Fosun Pharma's indirect equity interest in the Company remains unchanged.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, 8 April 2026

As at the date of this announcement, the Board comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *for identification purposes only*